Management of Minimal Hepatic Encephalopathy (MHE) in Cirrhosis

Screening and Diagnosis

The American Association for the Study of Liver Diseases recommends that all patients with cirrhosis should be treated with non-absorbable disaccharides (lactulose) or rifaximin to improve quality of life and reduce the risk of progression to overt hepatic encephalopathy 1
Active screening for MHE is essential in all cirrhotic patients, as this condition affects 30-84% of patients with cirrhosis and has profound impacts on daily functioning despite the absence of obvious clinical symptoms 2, 3
The Animal Naming Test is the preferred bedside screening tool, requiring no equipment, taking only 60 seconds to perform, and having limited spontaneous variability making it useful for monitoring 2, 3, 1

Lactulose is the primary treatment for MHE, with the goal of producing 2-3 soft stools daily 1
Rifaximin (1,200 mg/day) is equally effective as lactulose for MHE treatment, with 73.7% achieving MHE reversal after 3 months compared to 69.1% with lactulose 1

Systematic identification and prevention of precipitating factors is essential to reduce MHE progression and improve treatment outcomes 1, 5
Hyponatremia should be maintained at serum sodium >135 mmol/L if possible, always >130 mmol/L, as it is an independent risk factor for HE and is associated with non-response to lactulose 5
Proton Pump Inhibitors (PPIs) should be systematically re-evaluated and discontinued if no formal indication exists, as they increase HE risk through gastric pH elevation, promoting small intestine bacterial overgrowth and dysbiosis 5
Benzodiazepines are contraindicated in patients with decompensated cirrhosis, as they independently increase HE risk 5

After initiating treatment, monitor neuropsychological performance using the Animal Naming Test or other validated measures 2, 3
Daily life autonomy and basic operational abilities should be monitored, as well as mental status changes that may indicate progression to overt HE 6, 7

Adequate protein intake is essential and should not be restricted, providing 1.2-1.5 g/kg protein intake daily 6, 7, 8
Ensure 35-40 kcal/kg daily energy intake, and maintain positive nitrogen balance to prevent weight loss with sarcopenia, which worsens HE 6, 7, 8